Clinical Trial Update: A Clinical Study of INTRAROSA® (Prasterone) Vaginal Inserts in Postmenopausal Vulvovaginal Atrophy [Phase 3]

View source ↗

Summary

Phase 3 clinical study of INTRAROSA (prasterone) vaginal inserts for postmenopausal vulvovaginal atrophy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postmenopausal Vulvovaginal Atrophy

Drugs mentioned

• Intrarosa (prasterone)

Snippet

Sponsor: Lee's Pharmaceutical Limited | Conditions: Postmenopausal Vulvovaginal Atrophy | Phase 3 | Status: COMPLETED